Atlas Trials

Kodiak Sciences Inc

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Kodiak Sciences Inc

RecordFirmDate
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK (NCT06990399)Kodiak Sciences Inc2025-07-30
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE (NCT06996080)Kodiak Sciences Inc2025-07-16
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK (NCT06556368)Kodiak Sciences Inc2024-08-23
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) (NCT06270836)Kodiak Sciences Inc2024-05-01
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) (NCT05066230)Kodiak Sciences Inc2021-09-07
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) (NCT04964089)Kodiak Sciences Inc2021-06-23
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (NCT04611152)Kodiak Sciences Inc2020-09-30
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (NCT04603937)Kodiak Sciences Inc2020-09-30
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (NCT04592419)Kodiak Sciences Inc2020-09-25
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (NCT04049266)Kodiak Sciences Inc2019-10-08
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO (NCT03790852)Kodiak Sciences Inc2018-12-26

Track Kodiak Sciences Inc automatically

Every clearance here is in the API, with alerts when new ones post.